Finding a Niche for Celgene's Otezla

Celgene's (NASDAQ: CELG  ) new psoriatic arthritis drug Otezla isn't going to beat the current offerings from AbbVie (NYSE: ABBV  ) , Johnson & Johnson (NYSE: JNJ  ) , and Amgen (NASDAQ: AMGN  ) on an efficacy basis.

But it doesn't have too. Unlike Humira, Remicade, Enbrel, and the rest of the injected or infused biologics, Otezla is taken orally, giving Celgene a distinct advantage over AbbVie, Johnson & Johnson, and Amgen.

That doesn't mean Otezla will be an instant blockbuster though. As Fool contributor Brian Orelli and health-care bureau chief Max Macaluso discuss in the video below, Celgene needs to find a sweat spot, positioning Otezla between oral generics and the biologics doctors are comfortable prescribing.

Looking for growth outside of biotech? Try these 6 stocks.
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2894720, ~/Articles/ArticleHandler.aspx, 7/31/2014 2:38:29 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement